Acadia Healthcare Company, Inc.

Valuation Analysis

About the Company

Acadia Healthcare Company, Inc. en bref

Acadia Healthcare Company, Inc. (ACHC) is currently trading at 21,68 € with a market capitalization of 2,0 Md €. The 52-week range spans from 9,96 € to 26,33 €; the current price is 17.6% below the yearly high. Year-over-year revenue growth stands at +7.6%.

💰 Dividende

Acadia Healthcare Company, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

14 analystes évaluent Acadia Healthcare Company, Inc. (ACHC) au consensus : Acheter. L'objectif de cours moyen est de 25,16 €, soit un potentiel de +16.03% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 11,33 € à 34,00 €.

Acadia Healthcare Company, Inc. : la thèse d'investissement en détail

Acadia Healthcare Company, Inc. (ACHC) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 16.03% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 38.6% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The PEG ratio at 1.37 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 8.58x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (38.6%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Acadia Healthcare Company, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.